+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
ID07371611

Phase III Study of Sintilimab With Chemotherapy Before and After Surgery for Locally Advanced Oral Squamous Cell Carcinoma

Led by Qunxing Li,MD · Updated on 2026-01-28

104

Participants Needed

1

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating perioperative treatment with sintilimab combined with chemotherapy in patients who have locally advanced oral squamous cell carcinoma, a common head and neck cancer. This phase III, multicenter, randomized clinical trial aims to improve survival outcomes, as patients remain at high risk of recurrence or metastasis despite standard surgery and postoperative radiotherapy or chemoradiotherapy. Recent studies suggest that adding immunotherapy during the perioperative period may enhance patient prognosis and has been recommended in clinical guidelines. Participants will be randomly assigned to one of two groups. The experimental group receives neoadjuvant sintilimab combined with chemotherapy before surgery, followed by postoperative treatment based on their pathological response. Patients showing a major pathological response MPR will continue with adjuvant sintilimab, while those without MPR will receive postoperative radiotherapy or chemoradiotherapy combined with sintilimab. The control group will undergo standard treatment with surgery followed by postoperative radiotherapy or chemoradiotherapy as needed. Throughout the study, participants will be closely monitored with radiologic assessments at baseline and before surgery. Researchers will evaluate event-free survival as the primary outcome over two years, along with secondary outcomes including overall survival, pathological response, and treatment-related side effects. Safety and adverse events will be tracked for about one year. The study expects to provide important information to optimize treatment strategies and improve outcomes for patients with this type of oral cancer.

CONDITIONS

Brief Title

Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma

Research Team

L

Liansheng Wang, PhD (Candidate)

Q

Qunxing Li, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here